FBXO32 and Sepsis: Importantly, treatment with GSK0660 reduced sepsis-induced loss of muscle mass (Figure 8B) and blunted (but did not completely prevent) sepsis-induced upregulation of FOXO1, atrogin-1 and MuRF1 mRNA (Figure 8C–E) and protein levels (Figure 8F–H).